LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) has received an average rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $12.8750.
Several research firms have weighed in on LFST. Barclays upped their target price on LifeStance Health Group from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Thursday, September 10th. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Weiss Ratings raised LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. BTIG Research upped their price objective on LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. Finally, Canaccord Genuity Group raised their price objective on LifeStance Health Group from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th.
Get Our Latest Stock Report on LifeStance Health Group
LifeStance Health Group Price Performance
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The firm’s quarterly revenue was up 26.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.01) EPS. On average, analysts anticipate that LifeStance Health Group will post 0.16 earnings per share for the current fiscal year.
Insider Activity at LifeStance Health Group
In other news, CTO Vukasin Paunovich sold 44,394 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $481,674.90. Following the completion of the transaction, the chief technology officer owned 247,446 shares of the company’s stock, valued at approximately $2,684,789.10. This represents a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Bessler sold 894,337 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the completion of the sale, the director owned 539,763 shares in the company, valued at approximately $5,467,799.19. The trade was a 62.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 14,671,917 shares of company stock worth $155,493,415 over the last three months. 3.50% of the stock is owned by insiders.
Institutional Trading of LifeStance Health Group
Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of LifeStance Health Group during the second quarter worth $389,293,000. Vanguard Group Inc. boosted its holdings in shares of LifeStance Health Group by 21.1% during the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after acquiring an additional 3,086,506 shares in the last quarter. Silversmith Partners I GP LLC bought a new stake in LifeStance Health Group during the 4th quarter worth $100,842,000. Dimensional Fund Advisors LP grew its position in LifeStance Health Group by 16.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock worth $66,038,000 after acquiring an additional 1,461,215 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after purchasing an additional 2,843,388 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.
About LifeStance Health Group
LifeStance Health Group, Inc is a behavioral health care company that provides outpatient mental health services through in-person and virtual appointments. Its platform connects patients with psychiatrists, psychologists, psychiatric nurse practitioners, therapists and other licensed clinicians.
The company offers services that may include psychotherapy, psychiatric evaluations, medication management and treatment for conditions such as anxiety, depression, attention-deficit/hyperactivity disorder and other behavioral health needs.
Read More
- Five stocks we like better than LifeStance Health Group
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
